Emerging Treatment Options for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

References

• Harvey PT. Common eye diseases of elderly people: identifying and treating causes of vision loss. Gerontology. 2003;49:1–11. doi:10.1159/000066507
   PubMed Web of Science ®Google Scholar
• Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol. 1988;32(6):375–413. doi:10.1016/0039-6257(88)90052-5
   PubMed Web of Science ®Google Scholar
• Holz FG, Strauss EC, Schmitz-Valckenberg S, van Lookeren CM. Geographic atrophy: clinical features and potential therapeutic approaches. Ophthalmology. 2014;121(5):1079–1091. doi:10.1016/j.ophtha.2013.11.023
   PubMed Web of Science ®Google Scholar
• Kawa MP, Machalinska A, Roginska D, Machalinski B. Complement system in pathogenesis of AMD: dual player in degeneration and protection of retinal tissue. J Immunol Res. 2014;2014:483960. doi:10.1155/2014/483960
   PubMed Web of Science ®Google Scholar
• Nebbioso M, Lambiase A, Cerini A, et al. Therapeutic approaches with intravitreal injections in geographic atrophy secondary to age-related macular degeneration: current drugs and potential molecules. Int J Mol Sci. 2019;20:1693. doi:10.3390/ijms20071693
   PubMed Web of Science ®Google Scholar
• Chiu C-J, Chang M-L, Zhang FF, et al. The relationship of major American dietary patterns to age-related macular degeneration. Am J Ophthalmol. 2014;158(1):118–127. doi:10.1016/j.ajo.2014.04.016
   PubMed Web of Science ®Google Scholar
• Xu H, Chen M. Targeting the complement system for the management of retinal inflammatory and degenerative diseases. Eur J Pharmacol. 2016;787:94–104. doi:10.1016/j.ejphar.2016.03.001
   PubMed Web of Science ®Google Scholar
• Boyer DS, Schmidt-Erfurth U, van Lookeren Campagne M, et al. The pathophysiology of geographic atrophy secondary to age-related macular degeneration and the complement pathway as a therapeutic target. Retina. 2017;37:819–835. doi:10.1097/IAE.0000000000001392
   PubMed Web of Science ®Google Scholar
• Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res. 2010;20:34–50. doi:10.1038/cr.2009.139
   PubMed Web of Science ®Google Scholar
• Cho H. Complement regulation: physiology and disease relevance. Korean J Pediatr. 2015;58:239–244. doi:10.3345/kjp.2015.58.7.239
   PubMedGoogle Scholar
• Jaffe GJ, Westby K, Csaky KG, et al. C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial. Ophthalmology. 2021;128:576–586. doi:10.1016/j.ophtha.2020.08.027
   PubMed Web of Science ®Google Scholar
• Iveric Bio. Iveric Bio announces positive Zimura 18 month data supporting the 12 month efficacy findings: continuous positive treatment effect with favorable safety profile in geographic atrophy secondary to age-related macular degeneration in a phase 3 trial; 2020. Available from: https://investors.ivericbio.com/news-releases/news-release-details/iveric-bio-announces-positive-zimura-18-month-data-supporting-12. Accessed October 20, 2021.
   Google Scholar
• ClinicalTrials.gov. A phase I study of ARC1905 (anti-C5 aptamer) in subjects with dry age-related macular degeneration. ClinicalTrials.gov Identifier: NCT00950638. Available from: https://clinicaltrials.gov/ct2/show/NCT00950638. Accessed January 10, 2023.
   Google Scholar
• Rezaei K A method for treating or preventing neovascular age-related macular degeneration. W O 2019/040397 A l ed: World Intellectual Property Organization – International Bureau; 2019.
   Google Scholar
• Iveric Bio I. Iveric bio announces positive zimura 18 month data supporting the 12 month efficacy findings: continuous positive treatment effect with favorable safety profile in geographic atrophy secondary to age-related macular degeneration in a phase 3 trial; 2020. Available from: https://investors.ivericbio.com/news-releases/news-release-details/iveric-bio-announces-positive-zimura-18-month-data-supporting-12. Accessed January 10, 2023.
   Google Scholar
• ClinicalTrials.gov. A phase 3 safety and efficacy study of intravitreal administration of Zimura (complement C5 inhibitor) ClinicalTrials.gov identifier: NCT04435366. Available from: https://clinicaltrials.gov/ct2/show/NCT04435366. Accessed January 10, 2023.
   Google Scholar
• Khanani AM, Patel SS, Staurenghi G, et al. GATHER2 pivotal phase 3 study results: efficacy of intravitreal avacincaptad pegol in geographic atrophy. Am Acad Ophthalmol. 2022;2022:1.
   Google Scholar
• ClinicalTrials.gov. A phase II, multicenter, randomized, single-masked, sham-controlled study of safety, tolerability and evidence of activity of intravitreal APL-2 therapy in patients with geographic atrophy (GA). ClinicalTrials.gov Identifier: NCT02503332. Available from: https://clinicaltrials.gov/ct2/show/NCT02503332. Accessed January 10, 2023.
   Google Scholar
• Heier J, Wykoff C, Singh R, et al. Efficacy of intravitreal pegcetacoplan in geographic atrophy: results from the DERBY and OAKS trials. Retina Society; 2021. Available from: https://investors.apellis.com/static-files/fe6d8c27-e1b2-4c87-b77f-aa5cb249bacf. Accessed January 10, 2023.
   Google Scholar
• NGM bio announces topline results from the CATALINE phase 2 trial of NGM621 in patients with geographic atrophy (GA) secondary to age-related macular degeneration; 2022. Available from: https://ir.ngmbio.com/node/9586/pdf. Accessed January 10, 2023.
   Google Scholar
• ClinicalTrials.gov. Safety and efficacy of brimonidine intravitreal implant in patients with geographic atrophy due to age-related macular degeneration (AMD) ClinicalTrials.gov identifier: NCT00658619. Available from: https://clinicaltrials.gov/ct2/show/NCT00658619. Accessed January 10, 2023.
   Google Scholar
• Doozandeh A, Yazdani S. Neuroprotection in Glaucoma. J Ophthalmic Vis Res. 2016;11:209–220. doi:10.4103/2008-322X.183923
   PubMedGoogle Scholar
• ClinicalTrials.gov. Safety and efficacy of brimonidine posterior segment drug delivery system in patients with geographic atrophy secondary to age-related macular degeneration clinicaltrials.gov identifier: NCT02087085. Available from: https://clinicaltrials.gov/ct2/show/NCT02087085. Accessed January 10, 2023.
   Google Scholar
• Kuppermann BD, Patel SS, Boyer DS, et al.; Brimo DDS Gen 1 Study Group. Phase 2 study of the safety and efficacy of brimonidine drug delivery system (brimo DDS) generation 1 in patients with geographic atrophy secondary to age-related macular degeneration. Retina. 2021;41(1):144–155. doi:10.1097/IAE.0000000000002789
   PubMed Web of Science ®Google Scholar
• Freeman WR, Bandello F, Souied EH, et al. Lopez; phase 2b study of brimonidine DDS: potential novel treatment for geographic atrophy. Invest Ophthalmol Vis Sci. 2019;60(9):971.
   Web of Science ®Google Scholar
• Waheed NK FOCUS interim results: GT005 gene therapy phase I/II study for the treatment of geographic atrophy. angiogenesis, exudation, and degeneration; 2021. Available from: https://www.gyroscopetx.com/wp-content/uploads/2021/02/Waheed-Focus_FINAL.pdf. Accessed January 10, 2023.
   Google Scholar
• ClinicalTrials.gov. Focus: first in human study to evaluate the safety and efficacy of GT005 administered in subjects with dry AMD” clinicaltrials.gov identifier: NCT03846193. Available from: https://clinicaltrials.gov/ct2/show/NCT03846193. Accessed January 10, 2023.
   Google Scholar
• Nielsen J, MacLaren RE, Heier JS, et al. Preliminary results from a first-in-human phase I/II gene therapy study (FOCUS) of subretinally delivered GT005, an investigational AAV2 vector, in patients with geographic atrophy secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci. 2022;6`7):1504.
   Google Scholar
• ClinicalTrials.gov. HORIZON: a Phase II study to evaluate the safety and efficacy of two doses of GT005. ClinicalTrials.gov Identifier: NCT04566445. Available from: https://clinicaltrials.gov/ct2/show/NCT04566445. Accessed January 10, 2023.
   Google Scholar
• ClinicalTrials.gov. EXPLORE: a phase II study to evaluate the safety and efficacy of two doses of GT005. ClinicalTrials.gov Identifier: NCT04437368. Available from: https://clinicaltrials.gov/ct2/show/NCT04437368. Accessed January 10, 2023.
   Google Scholar
• ClinicalTrials.gov. A phase 1, open-label, multi-center, dose-escalating, safety and tolerability study of a single intravitreal injection of AAVCAGsCD59 in patients with advanced non-exudative (dry) age-related macular degeneration with geographic atrophy. ClinicalTrials.gov Identifier: NCT03144999. Available from: https://clinicaltrials.gov/ct2/show/NCT03144999. Accessed January 10, 2023.
   Google Scholar
• Dugel PU Data on a gene therapy for dry and wet AMD A phase 1 clinical trial program is targeting both disease states. Available from: https://www.retinalphysician.com/issues/2020/april-2020/clinical-trial-download-data-on-a-gene-therapy-for. Accessed January 10, 2023.
   Google Scholar
• Cho MS, Kim SJ, Ku SY, et al. Generation of retinal pigment epithelial cells from human embryonic stem cell-derived spherical neural masses. Stem Cell Res. 2012;9:101–109. doi:10.1016/j.scr.2012.05.002
   PubMed Web of Science ®Google Scholar
• Du H, Lim SL, Grob S, Zhang K. Induced pluripotent stem cell therapies for geographic atrophy of age-related macular degeneration. Semin Ophthalmol. 2011;263:216–224. doi:10.3109/08820538.2011.577498
   Google Scholar
• ClinicalTrials.gov. Safety and efficacy study of opregen for treatment of advanced dry-form age-related macular degeneration clinicalTrials.gov identifier: NCT02286089. Available from: https://clinicaltrials.gov/ct2/show/NCT02286089. Accessed January 10, 2023.
   Google Scholar